Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
Agenus (NASDAQ: AGEN) announced two upcoming presentations featuring BOT/BAL at the AACR IO Annual Meeting in Los Angeles (February 23-26). The first presentation will showcase interim data from a Phase 2 study combining botensilimab and balstilimab (BOT/BAL) with MiNK Therapeutics' iNKT cell therapy (AgenT-797) in refractory gastric cancer patients.
The second presentation will be a Trial-in-Progress poster highlighting data from an ongoing Phase 1/2 study of BOT/BAL in first-line MSS colorectal cancer. The presentations are scheduled for February 24th and 25th, covering biomarker analysis and treatment optimization strategies.
Agenus (NASDAQ: AGEN) ha annunciato due prossime presentazioni che presenteranno BOT/BAL durante il AACR IO Annual Meeting a Los Angeles (23-26 febbraio). La prima presentazione mostrerà dati intermedi di uno studio di Fase 2 che combina botensilimab e balstilimab (BOT/BAL) con la terapia cellulare iNKT di MiNK Therapeutics (AgenT-797) in pazienti con cancro gastrico refrattario.
La seconda presentazione sarà un poster Trial-in-Progress che evidenzierà i dati di uno studio in corso di Fase 1/2 di BOT/BAL nel trattamento di prima linea del cancro colorettale MSS. Le presentazioni sono programmate per il 24 e 25 febbraio, e tratteranno analisi dei biomarcatori e strategie di ottimizzazione del trattamento.
Agenus (NASDAQ: AGEN) anunció dos próximas presentaciones que presentarán BOT/BAL en la AACR IO Annual Meeting en Los Ángeles (23-26 de febrero). La primera presentación mostrará datos intermedios de un estudio de Fase 2 que combina botensilimab y balstilimab (BOT/BAL) con la terapia celular iNKT de MiNK Therapeutics (AgenT-797) en pacientes con cáncer gástrico refractario.
La segunda presentación será un póster Trial-in-Progress que destacará datos de un estudio en curso de Fase 1/2 de BOT/BAL en cáncer colorrectal MSS en primera línea. Las presentaciones están programadas para el 24 y 25 de febrero, cubriendo análisis de biomarcadores y estrategias de optimización del tratamiento.
Agenus (NASDAQ: AGEN)는 로스앤젤레스에서 열리는 AACR IO Annual Meeting (2월 23-26일)에서 BOT/BAL을 주제로 한 두 개의 발표를 예고했습니다. 첫 번째 발표에서는 난치성 위암 환자에 대한 botensilimab과 balstilimab (BOT/BAL) 및 MiNK Therapeutics의 iNKT 세포 요법 (AgenT-797)과의 병용에 대한 2상 연구의 중간 데이터를 소개할 것입니다.
두 번째 발표는 1/2상 연구의 진행 중인 데이터에 대한 Trial-in-Progress 포스터로, 1차 MSS 대장암에서의 BOT/BAL의 데이터를 강조할 것입니다. 발표는 2월 24일과 25일에 예정되어 있으며, 바이오마커 분석 및 치료 최적화 전략을 다룰 것입니다.
Agenus (NASDAQ: AGEN) a annoncé deux présentations à venir mettant en vedette BOT/BAL lors de la AACR IO Annual Meeting à Los Angeles (23-26 février). La première présentation présentera des données intermédiaires d'une étude de Phase 2 combinant botensilimab et balstilimab (BOT/BAL) avec la thérapie cellulaire iNKT de MiNK Therapeutics (AgenT-797) chez des patients atteints de cancer gastrique réfractaire.
La deuxième présentation sera une affiche Trial-in-Progress mettant en avant des données d'une étude en cours de Phase 1/2 de BOT/BAL dans le cancer colorectal MSS de première ligne. Les présentations sont prévues pour les 24 et 25 février, couvrant l'analyse des biomarqueurs et les stratégies d'optimisation du traitement.
Agenus (NASDAQ: AGEN) hat zwei bevorstehende Präsentationen angekündigt, die BOT/BAL auf dem AACR IO Annual Meeting in Los Angeles (23.-26. Februar) vorstellen werden. Die erste Präsentation wird Zwischenberichte aus einer Phase-2-Studie zeigen, die botensilimab und balstilimab (BOT/BAL) mit der iNKT-Zelltherapie von MiNK Therapeutics (AgenT-797) bei refraktären Magenkrebspatienten kombiniert.
Die zweite Präsentation wird ein Trial-in-Progress-Poster sein, das Daten aus einer laufenden Phase-1/2-Studie zu BOT/BAL bei erstlinigem MSS-Dickdarmkrebs hervorhebt. Die Präsentationen sind für den 24. und 25. Februar geplant und behandeln die Analyse von Biomarkern und Strategien zur Optimierung der Behandlung.
- Phase 2 clinical trial progress in gastric cancer treatment
- Ongoing Phase 1/2 trial in first-line MSS colorectal cancer
- Multiple presentation opportunities at major industry conference
- None.
Presentation Details:
Abstract Title: First-line botensilimab and balstilimab optimization in microsatellite stable colorectal cancer (MSS-CRC) without liver metastasis (BBOpCo)
Session: Poster Session A
Session Date and Time: Monday, February 24th, 1:45-4:45 p.m. PST
Abstract Title: Biomarker analysis from phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC)
Session: Proffered Papers, Session 2
Session Date and Time: Tuesday, February 25th, 1:00-1:45 p.m. PST
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in
About Botensilimab (BOT)
Botensilimab (BOT) is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies.
Approximately 1,100 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316.
About Balstilimab (BAL)
Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.
About AgenT-797
AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy, leveraging a unique innate immune cell type that serves as a master regulator of both innate and adaptive immunity. iNKTs combine the cytotoxic capabilities of natural killer (NK) cells with the adaptive memory of T cells, enabling them to elicit a broad range of immune responses in a pathogen-agnostic manner.
AgenT-797 is a scalable, “off-the-shelf” cell therapy product, manufactured by MiNK Therapeutics in
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250212738181/en/
Investors
917-362-1370
investor@agenusbio.com
Media
510-323-5188
communications@agenusbio.com
Source: Agenus Inc.
FAQ
What are the two presentations about BOT/BAL that Agenus (AGEN) will present at AACR IO 2024?
When and where will Agenus (AGEN) present its BOT/BAL data at AACR IO 2024?
What is the focus of Agenus (AGEN)'s Phase 2 study in gastric cancer?
What type of cancer is being targeted in Agenus (AGEN)'s Phase 1/2 BOT/BAL study?
